Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Praziquantel is a small molecule anthelmintic medication used to treat a variety of parasitic worm infections, including schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections (such as taeniasis and cysticercosis), echinococcosis, paragonimiasis, fasciolopsiasis, and fasciolosis in humans[3][5]. It is also used in veterinary medicine for similar indications. Praziquantel works primarily by disrupting calcium ion homeostasis in susceptible worms through antagonism of voltage-gated calcium channels. This leads to increased permeability of the parasite's cell membranes to calcium ions, resulting in paralysis and death of the worm[6][3]. The drug was first approved for medical use in 1982 and is included on the World Health Organization's List of Essential Medicines due to its efficacy and low cost[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on praziquantel.